

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 7/26/1961
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG CBA-IFA and Contactin-Associated Protein-2 Antibody, IgG CBA-IFA with Reflex to Titers, Serum

ARUP test code 2009460

CASPR2 Ab IgG CBA-IFA Screen, Serum

Detected * (Ref Interval: <1:10)

CASPR2 Antibody, IgG is detected. Titer results to follow.

INTERPRETIVE INFORMATION: CASPR2 Ab IgG by IFA, Serum

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy and Morvan syndrome. Tumors such as thymoma, small-cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

LGI1 Ab IgG CBA-IFA Screen, Serum

Detected * (Ref Interval: <1:10)

LGI1 Antibody, IgG is detected. Titer results to follow.

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: LGI1 Ab IgG Screen by IFA, Serum

Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes leucine-rich, glioma-inactivated 1 protein (LGI1) transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Contactin-Associated Protein-2 Antibody Titer, IgG by CBA-IFA, Serum (Reflex for 2009452 CASPR2 IGG Only - Not Orderable by Clients)

ARUP test code 2009454

CASPR2 Ab IgG CBA-IFA Titer, Serum

1:20 * (Ref Interval: <1:10)

INTERPRETIVE INFORMATION: CASPR2 Ab Titer IgG by IFA, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Leucine-Rich, Glioma-Inactivated Protein 1 Antibody Titer, IgG by CBA-IFA, Serum (Reflex for 2009456 LGI1 IGG Only - Not Orderable by Clients)

ARUP test code 2009458

LGI1 Ab IgG CBA-IFA Titer, Serum

1:20 * (Ref Interval: <1:10)

INTERPRETIVE INFORMATION: LGI1 Ab Titer IgG by IFA, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
CASPR2 Ab IgG CBA-IFA Screen, Serum	23-111-133140	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CASPR2 Ab IgG CBA-IFA Titer, Serum	23-111-133140	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG CBA-IFA Screen, Serum	23-111-133140	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
LG11 Ab IgG CBA-IFA Titer, Serum	23-111-133140	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-111-133140
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 12/14/2023 12:02:06 PM
4848